Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | HRH2 | P25021 | 4/20 | 0.53 |
| ▸ | HRH1 | P35367 | 4/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714612 | 0.86 | HRH3 (0.60) | DRD2HRH3HRH2HRH1 | |
| SCHEMBL7244497 | 0.86 | HRH1 (0.60) | HRH3HRH2HRH1 | |
| SCHEMBL25080803 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9MGLL | |
| SCHEMBL3129914 | 0.84 | KCNH2 (0.54) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL1714805 | 0.84 | HRH2 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL7249427 | 0.83 | HRH1 (0.62) | HRH3HRH2HRH1 | |
| SCHEMBL2964384 | 0.82 | KCNH2 (0.56) | HRH3CA12CA1CA2CA9 | |
| SCHEMBL13140981 | 0.82 | CA12 (0.64) | CA12CA1CA2CA9MGLL | |
| SCHEMBL7245807 | 0.81 | HRH2 (0.71) | HRH3HRH2HRH1 | |
| SCHEMBL3128796 | 0.81 | KCNH2 (0.51) | DRD2HRH3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | DRD2 1292/4885HRH3 395/4885CA12 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.